Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. CPX-351 (VYXEOS) for elderly patients with newly diagnosed acute myeloid leukaemia – first line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Acute myeloid leukaemia is a rare type of cancer that affects the way blood cells are developed so that they do not work properly. This leads to an increased risk of infection, as well as symptoms such as anaemia and bruising. It can affect people at any age but is more common in people over 65.
Chemotherapy drugs can be very effective in the treatment of acute myeloid leukaemia. In some situations, these drugs are combined with stem cell or bone marrow transplant to improve the chances of curing the leukaemia. However, some patients cannot tolerate intensive chemotherapy and non-intensive treatments are offered.
CPX-351 is a new product aimed at patients aged 60 years or older which delivers two of the most commonly used drugs in the treatment of acute myeloid leukaemia (cytarabine and daunorubicin) in a new combination.
If CPX-351 is licensed for use in the UK, it could be a new treatment option for these patients. A current trial is looking to see whether CPX-351 can improve survival compared to an existing treatment, and whether it is safe to use. Indexing Status Subject indexing assigned by CRD MeSH Aged; Anthracyclines; Antibiotics, Antineoplastic; Humans; Leukemia, Myeloid, Acute; Pyrimidines Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000742 Date abstract record published 14/06/2016 |